All In Biotech

Drug Trial Radar · NCT04469595

A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)

A Randomized, Masked, Controlled Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)

Last checked: Nov 19, 2026Latest source record: Jul 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Aug 31, 2020

Primary completion

Dec 31, 2024

Study completion Dec 31, 2024

Sponsor

Lead sponsor
Alimera SciencesIndustry
Sponsor type
Industry
First posted
Jul 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, masked, active-controlled, parallel-group, multi-center study that will assess the efficacy of ILUVIEN as a baseline therapy in the treatment of Center Involving DME (CI-DME). The study will enroll patients who are either treatment naïve or have not received any DME treatments for the preceding 12 months as documented in medical records. Patients who received DME treatment \>12 months before screening, must not have received \>4 intravitreal injections. The study will compare 2 treatment regimens: ILUVIEN intravitreal implant (0.19 mg) followed by supplemental aflibercept as needed per protocol criteria (2 mg/0.05 mL), compared to intravitreal aflibercept loading dose (2 mg administered by intravitreal injection every 4 weeks for 5 consecutive doses) followed by supplemental aflibercept as needed per protocol criteria (2 mg/0.05 mL).

Conditions

  • Diabetic Macular Edema

Interventions

  • Iluvien 0.19 MG Drug ImplantDrug

    0.19 mg Fluocinolone Acetonide Intravitreal Implant

  • AfliberceptDrug

    2 mg/0.05 mL Aflibercept Anti-VEGF intravitreal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The mean total number of supplemental aflibercept injections needed during the studyTime frame: Baseline to 18 months

Locations

40 sites in 1 country. Site status is shown where the registry gives one.

  • Investigative Site

    Phoenix, Arizona

  • Investigative Site

    Tucson, Arizona

  • Investigative Site

    Beverly Hills, California

  • Investigative Site

    Glendale, California

  • Investigative Site

    Laguna Hills, California

  • Investigative Site

    Santa Ana, California

  • Investigative Site

    Colorado Springs, Colorado

  • Investigative Site

    Clearwater, Florida

  • Investigative Site

    Orlando, Florida

  • Investigative Site

    Palm Beach Gardens, Florida

  • Investigative Site

    Tampa, Florida

  • Investigative Site

    Marietta, Georgia

  • Investigative Site

    Sandy Springs, Georgia

  • Investigative Site

    Elmhurst, Illinois

  • Investigative Site

    Lemont, Illinois

  • Investigative Site

    Oak Park, Illinois

  • Investigative Site

    Springfield, Illinois

  • Investigative Site

    Leawood, Kansas

  • Investigative Site

    Shawnee Mission, Kansas

  • Investigative Site

    West Monroe, Louisiana

  • Investigative Site

    Baltimore, Maryland

  • Investigative Site

    Detroit, Michigan

  • Investigative Site

    Grand Blanc, Michigan

  • Investigative Site

    Independence, Missouri

  • Investigative Site

    Bloomfield, New Jersey

  • Investigative Site

    Beachwood, Ohio

  • Investigative Site

    Cincinnati, Ohio

  • Investigative Site

    Cleveland, Ohio

  • Investigative Site

    Youngstown, Ohio

  • Investigative Site

    Tulsa, Oklahoma

  • Investigative Site

    Erie, Pennsylvania

  • Investigative Site

    Columbia, South Carolina

  • Investigative Site

    Dallas, Texas

  • Investigative Site

    Houston, Texas

  • Investigative Site

    McAllen, Texas

  • Investigative Site

    San Antonio, Texas

  • Investigative Site

    San Antonio, Texas

  • Investigative Site

    The Woodlands, Texas

  • Investigative Site

    Roanoke, Virginia

  • Investigative Site

    Warrenton, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.